

## Journal of General Virology

## Genotyping coronaviruses associated with feline infectious peritonitis

--Manuscript Draft--

<b>Manuscript Number:</b>	JGV-D-14-00253R1
<b>Full Title:</b>	Genotyping coronaviruses associated with feline infectious peritonitis
<b>Short Title:</b>	FCoV in cats with feline infectious peritonitis
<b>Article Type:</b>	Standard
<b>Section/Category:</b>	Animal - Positive-strand RNA Viruses
<b>Corresponding Author:</b>	Stuart G. Siddell, BSc PhD University of Bristol Bristol, UNITED KINGDOM
<b>First Author:</b>	Catherine S. Lewis
<b>Order of Authors:</b>	Catherine S. Lewis Emily Porter David Matthews Anja Kipar Severine Tasker Christopher R. Helps Stuart G. Siddell, BSc PhD
<b>Abstract:</b>	Feline coronavirus (FCoV) infections are endemic amongst cats worldwide. The majority of infections are asymptomatic, or result only in mild enteric disease. However, approximately 5% of cases develop feline infectious peritonitis (FIP), a systemic disease that is a frequent cause of death in young cats. In this study, we report the complete coding genome sequences of six FCoVs; three from fecal samples from healthy cats and three from tissue lesion samples from cats with confirmed FIP. The six samples were obtained over a period of eight weeks at a single-site cat rescue and rehoming center in the UK. We found amino acid differences are located at 44 positions across an alignment of the six virus translatoemes and, at 21 of these positions, the differences fully or partially discriminate between the genomes derived from the fecal samples and the genomes derived from tissue lesion samples. In this study, two amino acid differences fully discriminate the two classes of genomes; these are both located in the S2 domain of the virus surface glycoprotein gene. We also identified deletions in the 3c protein ORF of genomes from two of the FIP samples. Our results support previous studies that implicate S protein mutations in the pathogenesis of FIP.

## **Genotyping coronaviruses associated with feline infectious peritonitis**

Catherine S Lewis<sup>1</sup>, Emily Porter<sup>2</sup>, David Matthews<sup>1</sup>, Anja Kipar<sup>3</sup>, Séverine Tasker<sup>2</sup>,  
Christopher R Helps<sup>2</sup>, and Stuart G Siddell<sup>1\*</sup>

5

<sup>1</sup> School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, United Kingdom

<sup>2</sup> School of Veterinary Sciences, University of Bristol, Langford, Bristol BS40 5DU, United Kingdom

10 <sup>3</sup> Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Winterthurer Strasse 268, 8057 Zurich, Switzerland

Contents category: Animal, RNA viruses

Running title: FCoV in cats with feline infectious peritonitis

15 Corresponding author: Stuart G Siddell, stuart.siddell@bristol.ac.uk, Tel. 00441173312067, Fax. 00441173312091

Word counts: Text, 5520, Summary 205

Tables: 3, Figures: 5, Supplementary file: 1

20 The GenBank accession numbers for the FCoV genomes reported here are KP143511 (80F), KP143509 (65F), KP143510 (67F), KP143512 (26M), KP143507 (27C) and KP143508 (28O)

## Summary

25 Feline coronavirus (FCoV) infections are endemic amongst cats worldwide. The majority of infections are asymptomatic, or result only in mild enteric disease. However, approximately 5% of cases develop feline infectious peritonitis (FIP), a systemic disease that is a frequent cause of death in young cats. In this study, we report the complete coding genome sequences of six FCoVs; three from fecal samples from healthy cats and three from  
30 tissue lesion samples from cats with confirmed FIP. The six samples were obtained over a period of eight weeks at a single-site cat rescue and rehoming center in the UK. We found amino acid differences are located at 44 positions across an alignment of the six virus translomes and, at 21 of these positions, the differences fully or partially discriminate between the genomes derived from the fecal samples and the genomes derived from tissue  
35 lesion samples. In this study, two amino acid differences fully discriminate the two classes of genomes; these are both located in the S2 domain of the virus surface glycoprotein gene. We also identified deletions in the 3c protein ORF of genomes from two of the FIP samples. Our results support previous studies that implicate S protein mutations in the pathogenesis of FIP.

## Keywords

Feline infectious peritonitis, coronavirus, genome, sequence

## Introduction

Coronaviruses are enveloped, positive-stranded RNA viruses. They are generally responsible for mild enteric and respiratory infections but they can also be associated with severe disease in both humans and animals (Masters & Perlman, 2013). Coronaviruses are now recognized as emerging viruses with a propensity to cross into new host species, as has been shown by the recent outbreaks of severe acute respiratory syndrome and Middle East respiratory syndrome (Coleman & Frieman, 2014). As illustrated in Fig.1 for feline coronavirus (FCoV), two-thirds of the coronavirus genome encodes proteins involved in viral RNA synthesis. The majority of these proteins are encoded in two 5'-proximal, overlapping open reading frames (ORFs), ORF1a and ORF1b, and are translated as polyproteins, pp1a and pp1ab, which are then processed by virus-encoded proteinases into 16 nonstructural proteins (Ziebuhr, 2005). The remainder of the genome encodes the virus structural proteins (S, E, M and N) as well as accessory proteins that are not essential for replication in cell culture. The structural and accessory proteins are translated from a 3' co-terminal nested set of subgenomic mRNAs (Perlman & Netland, 2009).

The coronavirus surface or spike (S) glycoprotein is a typical class 1 viral fusion protein and it has a central role in the biology of coronavirus infection. Structurally, the protein can be divided into an amino-proximal half, the S1 domain, which contains the receptor-binding domain and a carboxyl-proximal half, the S2 domain, which contains elements involved in membrane fusion. These elements include heptad repeats, a fusion peptide and a carboxyl-terminal, hydrophobic transmembrane domain (Heald-Sargent & Gallagher, 2012). In many coronaviruses, the S1 and S2 domains are cleaved from each other by a cellular, furin-like enzyme (de Haan *et al.*, 2004). The S protein is also the location of both B cell and T cell epitopes that are important in virus neutralization and the recognition of virus-infected cells (Reguera *et al.*, 2012; Satoh *et al.*, 2011).

70 FCoV form two antigenically distinct serotypes; serotype 1, which are difficult to propagate in cell culture, and serotype 2, which are the consequence of a double recombination between type 1 FCoV<sup>1</sup> and canine coronavirus (Herrewegh *et al.*, 1998) and are relatively easy to propagate in cell culture. FCoV infections are endemic amongst cats worldwide, and serological and molecular studies confirm that serotype 1 FCoVs  
75 predominate (Pedersen, 2014b). In the United Kingdom about 40% of domestic cats have been infected with FCoV and in multicat households this figure increases to almost 90% (Addie, 2000; Addie & Jarrett, 1992). The majority of FCoV infections are asymptomatic, or result only in mild enteric disease. However, approximately 5% of infected cats develop feline infectious peritonitis (FIP), a systemic inflammatory disease that is a frequent cause of death  
80 in young cats (Kipar & Meli, 2014). Currently, there is no protective vaccine or effective treatment for FIP (Pedersen, 2009; 2014a).

The most important questions in FCoV research are why some infected animals remain relatively healthy, whilst others develop FIP, and what is the role of the virus in the development of disease. It is now widely accepted that, in the vast majority of cases, cats are  
85 infected by the fecal-oral route with avirulent FCoV strains circulating in the cat population. Initially, this virus replicates predominantly in the intestinal epithelium and is shed with the feces. Nonetheless, it often leads to systemic infection via monocyte-associated viremia (Kipar *et al.*, 2010; Meli *et al.*, 2004; Porter *et al.*, 2014). At this stage, however, the systemic infection is characterized by a relatively low level of virus replication and infection can be  
90 maintained for a prolonged period of time, possibly involving recurrent viremic events, without apparent disease (Kipar *et al.*, 2010). During replication in the intestine or, potentially, within monocytes/macrophages (Pedersen *et al.*, 2012), the virus undergoes mutation and viruses with an enhanced tropism for monocytes and macrophages emerge. The altered

---

<sup>1</sup> In this paper, unless otherwise stated, FCoV will be used to mean serotype 1 FCoV. FCoV is also used as a strain designation for the species *Alphacoronavirus 1* in the genus *Alphacoronavirus*, family *Coronaviridae*.

tropism of these mutants results in their ability to maintain effective and sustainable  
95 replication in monocytes (Dewerchin *et al.*, 2005). As a direct or indirect result of a higher  
level of virus replication, this now apparently virulent virus leads to activation of monocytes  
(Regan *et al.*, 2009), which can then interact with endothelial cells. This, in turn, mediates  
granulomatous phlebitis and periphlebitis, the morphological hallmark and initiating lesion of  
FIP (Kipar *et al.*, 2005).

100 In addition to the virus, the susceptibility of the individual infected cat to disease also  
plays a significant role and it has been shown that age, breed, gender, reproductive status  
and immune response influences the development of FIP (Pedersen, 2014b; Pedersen *et al.*,  
2014). For example, the efficacy of early T cell responses critically determines the disease  
outcome in cats that have been experimentally infected with a virulent serotype 2 strain,  
105 FIPV 79-1146 (de Groot-Mijnes *et al.*, 2005). Furthermore, there is individual variation in the  
susceptibility of a cat's monocytes to FCoV (Dewerchin *et al.*, 2005). Also, recently, single  
nucleotide polymorphisms in the feline interferon- $\gamma$  gene have been linked to both resistance  
and susceptibility to the development of FIP (Hsieh & Chueh, 2014). Clearly, unraveling the  
relationship between FCoV genotypes and phenotypes, and the complex interactions  
110 between the virus and host during the development of FIP remains a major challenge.

One facet of this challenge is to determine the mutations that alter the tropism and  
virulence of FCoV. As a first step, this can be done by comparing the genomic sequences of  
viruses shed in the feces of healthy animals and viruses that predominate within tissue  
lesions of cats that have been diagnosed with FIP. This approach assumes that the most  
115 highly abundant genome in a population is responsible for a particular disease phenotype,  
which is, however, consistent with our current understanding of FIP epidemiology. Using this  
approach, a recent paper published by Chang *et al.* (Chang *et al.*, 2012) provided evidence  
for an association between FCoV virulence and amino acid substitutions within the putative  
fusion peptide of the FCoV spike (S) protein. A more detailed examination of samples from

120 FCoV infected cats that did not have histopathological evidence of FIP, led Porter *et al.*  
(Porter *et al.*, 2014) to conclude that these substitutions were indicative of systemic spread,  
rather than a virus that, without further mutation, is able to cause FIP. As the S protein fusion  
peptide is involved in the fusion of viral and cellular membranes during virus entry, it seems  
plausible that changes within this region may be linked to the tropism of the virus.

125 Similarly, Licitra *et al.* (Licitra *et al.*, 2013) were able to distinguish between FCoVs in  
cats with and without FIP on the basis of one or more substitutions in the amino acid  
sequence that comprises the furin cleavage site within the FCoV S protein. The authors  
demonstrated that these substitutions modulated furin cleavage and suggested that a  
possible consequence of the identified substitutions is an enhanced cleavability by  
130 alternative, monocyte/macrophage specific proteases.

Finally, there have been many reports over the years of point mutations and indels in  
the accessory protein genes of FCoVs and claims that these may be linked to the  
development of FIP. Prominent amongst these are reports that truncating and non-truncating  
mutations in the ORF3c gene occur in a significant proportion but not all FCoVs associated  
135 with FIP (Chang *et al.*, 2010; Pedersen *et al.*, 2012). However, the role of the FCoV 3c  
protein and any relationship to the development of FIP is still unclear. One view is that  
functional 3c protein expression is essential for replication in the gut but is dispensable for  
systemic replication. Thus, once the virus has left the gut there is no further selection  
pressure to maintain an intact 3c gene and mutations will accumulate over time. This  
140 interpretation does not exclude the possibility that the loss or alteration of the 3c protein may  
enhance the fitness of the virus in the monocyte/macrophage environment but this is not yet  
supported by any convincing evidence. Similarly, whilst the genes encoding the 3a, 3b, 7a  
and 7b proteins clearly have important functions that will impact on virus fitness (Haijema *et al.*, 2004), there is, as yet, no evidence that links specific mutations in these genes to the  
145 development of FIP.

In this study, we report the genome sequences of six FCoV; three from fecal samples from healthy cats and three from tissue lesion samples from cats with confirmed FIP. The six samples were obtained from cats that were resident at a single-site cat rescue and rehoming center in the UK. Our results support and extend previous studies that implicate S protein mutations in the pathogenesis of FIP.



## Results

### *FCoV RNA in fecal and tissue lesion samples*

155 As a first step, we amplified the FCoV RNA in fecal and tissue lesion samples. The seven amplicons for each of the fecal-derived RNA samples were of the expected size and were produced in approximately equal amounts. In comparison, there was greater heterogeneity in the amplicons obtained from RNA isolated from the FIP tissue lesions (Fig. 2). Specifically, there was more evidence of non-specific products and, especially in the case of amplicon 6, 160 which encompasses the region of the genome encoding the S protein gene, there was less product than expected. In this context, we noted that the Ct values were generally higher (i.e. less viral RNA) for fecal samples than for samples from the FIP tissue lesions. The mean Ct values for the 65F, 67F and 80F fecal total RNA samples were 20.9, 16.9 and 29.0, respectively and the mean Ct values for the 26M, 27C and 28O tissue lesion samples were 165 14.0, 21.5 and 15.0, respectively. One explanation for the difference in homogeneity of amplicons derived from fecal and lesional samples may be that the samples derived from lesions contain significantly greater amounts of FCoV subgenomic mRNA than the fecal samples, which would be expected to contain mainly virion particles. Also, immunohistochemistry identified a large number of macrophages with abundant viral antigen 170 (i.e. N protein) within the lesions (data not shown). It is therefore very likely that the RNA extracted from the lesions contains much more viral mRNA than the feces. Thus, in the RT-PCR reactions that involve RNA from tissues, many of the oligonucleotide primers would bind to multiple templates, resulting in a more complex amplicon pattern.

### 175 *Assembly of genome sequences*

Using the methods described, we were able to obtain full genome coverage, with a minimum depth of 1000 reads at each base across the coding region (Fig. 3). We expect that with further optimization, it would be possible to obtain an acceptable level of coverage and depth for more than 4 complete genomes per single 316v2 chip. Similarly, it would also be

possible to obtain a very high density of reads for a single genome if, for example, the goal was to investigate the nature of the viral quasispecies in a particular sample. In our opinion, the limiting step in genome sequencing from clinical samples is the production of amplicons but, once this has been achieved, the downstream processing is relatively straight forward.

Our approach was based upon the alignment of sequence reads to a *de novo* assembled target genome and this is dependent upon a relatively high similarity between samples. For example, in the case of the 65F, 67F, 26M and 28O samples, the percentages of reads that aligned to the 80F target genome were 96%, 95%, 90% and 95% respectively. However, only 76.8% of reads from the 27C sample aligned to the 80F target genome. Thus, for the 27C sample, the *de novo* assembly method had to be used. *De novo* assembly is more time consuming and would not be a good approach if every sample had to be analyzed in this manner, as would be the case if they were highly divergent. It should also be noted that in our analysis, we have only compared genome consensus sequences where each position is defined by a single nucleotide. In reality, for any sample, many nucleotide positions are represented by a proportion of different nucleotides. In these cases, we have taken the majority nucleotide as the consensus nucleotide and have not attempted to delineate different populations in the quasispecies. This means that when comparing sequences, we are only able to identify mutations throughout the population of genomes and do not conclude that any or all of these mutations are found in a single genomic RNA.

## *Phylogenetic analysis*

Phylogenetic analysis of the six clinical samples described here, based upon the conserved RNA-dependent RNA polymerase (RdRp), shows that they comprise a closely related cluster (Fig. 4). As reported by Barker *et al.* (Barker *et al.*, 2013), there is no evidence that the samples derived from FIP or non-FIP animals represent genetically diverse co-circulating strains, which provides further support for the “internal mutation” hypothesis. However, it is very difficult to exclude the possibility that at least some of the mutations that

may contribute to the development of FIP are present in a minor component of the infecting population, which is subsequently selected during virus replication *in vivo*.

## 210 *Comparison of FCoV genome sequences from clinical samples*

The genome sequences of the six FCoVs derived from fecal and tissue lesion samples were translated into two polyproteins (pp1a and pp1ab), four structural proteins (S, M, N and E) and 5 accessory proteins (3s, 3b, 3c, 7a and 7b). We found that amino acid differences are located at 44 positions across an alignment of the six translato-  
215 mes. At 21 of these positions, the differences fully or partially discriminate between the genomes derived from fecal (i.e. non-FIP) samples and from tissue (i.e. FIP) samples. More specifically, in these 21 positions one, or more, of the translato-  
220 mes from the FIP samples displays an amino acid that is not found at the corresponding position in the translato-  
mes from any of the non-FIP samples (Table 1). We also identified deletions in the 3c protein ORF of genomes from  
two of the FIP samples.

The fully discriminatory differences we identified are located at two positions where a different amino acid is found in all three FIP translato-  
mes compared to all three non-FIP translato-  
mes. The first of these is at nucleotide position 23302 and corresponds to the methionine to leucine substitution identified by Chang *et al.* (Chang *et al.*, 2012). Thus, our  
225 data support the idea that this substitution may be critical with regard to the pathogenesis of FIP. The second fully discriminatory substitution we identified, which was present in all of the FIP samples but none of the non-FIP samples, was at nucleotide position 23486 and resulted in an isoleucine to threonine substitution in the heptad repeat region 1 (HR1) of the S2 domain in the FCoV S protein. The possible significance of this substitution is discussed in  
230 more detail below.

Apart from the fully discriminatory substitutions described above, Table 1 shows a further 19 positions where one or two of the translato-  
mes from the FIP samples displays an amino acid that is not found at the corresponding position in the translato-  
mes from non-FIP samples. Without any further information, it is difficult to conclude that any of these

235 substitutions, alone or in combination, may be related to the development of FIP. However, they should not be ignored. For example, the substitutions resulting from mutations at positions 22528 and 22539 both lie within the furin cleavage motif that separates the S1 (receptor-binding) and S2 (fusion) domains of the FCoV S protein. Both substitutions (R789G at P4 and R792S at P1, where P4 and P1 designate positions in the canonical furin cleavage 240 motif) would be predicted to alter furin cleavage activity. If this is the case, our results support the conclusions of Licitra *et al.* (Licitra *et al.*, 2013) that identify the furin cleavage site as a potentially important region in the development of FIP. Alternatively, it could be argued that once the virus has acquired a tropism for the monocyte/macrophage, cleavage at the furin recognition motif may no longer be relevant to virus entry and mutations may accumulate 245 due to a lack of selection pressure. For coronaviruses such as mouse hepatitis virus (MHV), cleavage at the canonical furin motif does not seem to be essential, at least for *in vitro* infectivity (Bos *et al.*, 1997), and recent results suggest that activation of the coronavirus S protein fusion activity requires proteolytic cleavage at a different position in the S2 subunit (Millet & Whittaker, 2014; Wicht *et al.*, 2014). Finally, Table 1 shows that two of the three 250 translomes derived from the FIP samples have a deletion in the 3c protein gene, which is not found in any of the non-FIP samples. In both cases, the deletion of 10 nucleotides leads to a translational frameshift that produces a 3c protein truncated eight amino acids downstream of the deletion site.

In addition to amino acid substitutions that partially or fully discriminate between the 255 genomes derived from non-FIP and FIP samples, our study has also identified a further 23 amino acid substitutions that do not discriminate between non-FIP and FIP genomes. These are listed in Table 2. These substitutions will not be discussed in detail but it is, perhaps, worth noting that the majority are found either in the nsp3 protein or the amino-proximal S1 region of the S protein. This suggests that these regions may represent the targets of 260 particularly strong selective pressures. In the case of the S1 region of the S protein, we speculate that this selective pressure is immunological and relates to production of neutralizing antibodies. The selective pressures that target the nsp3 protein are unknown.

For completeness, we also note that we identified a single G to T mutation in the 3' UTR at position 28926 of the consensus sequence derived from the 26M sample that was not found  
265 in any other sample.

## Discussion

This study demonstrates an approach to the complete genome sequencing of FCoV derived from clinical material that is achievable in a standard laboratory setting. It is based upon the generation of a virus-specific cDNA library using oligonucleotide primer pairs, followed by next generation sequencing (NGS) on a commercial platform, and downstream genome assembly using free software that will run on a personal computer. This approach was taken after we had failed to determine complete genome sequences of FCoV from clinical samples using a randomly primed cDNA library followed by NGS (Porter, PhD thesis, University of Bristol, 2014). In the study reported here, complete genome sequencing was achieved for six FCoVs using only seven primer pairs. However, the samples we used were all collected within a few months at a single location, which means that they are less likely to have diverged, compared to samples taken at different locations over a longer time period. As the number of complete genome sequences for both serotype 1 and serotype 2 FCoVs increases, it may be possible to design a set of universal primer pairs that will only require minor optimization to successfully sequence any FCoV genome. In our own laboratory, we have shown that the seven primer pairs described here are able to produce amplicons of the expected size in approximately two-thirds of geographically divergent UK fecal samples collected over a 2 year period (unpublished results).

In addition to confirming earlier findings, the most interesting result of this study is undoubtedly the identification of a consistent substitution of isoleucine with threonine at amino acid position 1108 in all FCoVs from FIP lesions compared to the fecal samples from healthy cats. This substitution is located within the heptad HR1 region of the S2 subunit of the FCoV S protein and could be interesting from two points of view. First, we note that this amino acid position has been identified as being located in a major T helper 1 epitope (I-S2-6, IGNITLALGKVSNAITTTSD) in a type 1 Japanese FCoV (KU-2) that was associated with FIP (Sato *et al.*, 2011). Obviously, further research will be required to ascertain whether there is a Th1 epitope spanning this amino acid sequence in non-FIP associated FCoVs, and

295 to determine the quantitative or qualitative effect that may result from the isoleucine to  
threonine substitution. However, de Groot-Mijnes *et al.* (de Groot-Mijnes *et al.*, 2005) have  
already drawn attention to the relationship between T cell depletion and the enhanced virus  
replication in FIP cases, although the mechanisms of T cell depletion are not yet clear. We  
suggest this is an area of FIP research that merits further study. For example, it would be  
300 interesting to compare IFN- $\gamma$  production by peripheral blood mononuclear cells taken from  
cats with FIP or healthy, FCoV-infected cats, and exposed separately to relevant HR1  
peptides, the sequences of which are derived from FIP and non-FIP associated FCoVs.

Second, a quite different interpretation of the HR1 isoleucine to threonine substitution  
is that it may be related to the fusogenic activity of the FCoV S protein. This is because the  
305 substitution also lies within a stretch of 15 amino acids (NAITTIISDGFNTMAS) that are  
found only in alphacoronaviruses and are part of the heptad repeat structure that  
characterizes the HR1 region. Indeed, the isoleucine/threonine position constitutes a residue  
predicted to be located on the hydrophobic interface of the coiled-coil structure. Substitution  
of a hydrophobic residue with a polar, uncharged residue may, at least theoretically,  
310 significantly influence the intercalation of HR1 and HR2 regions, which is a necessary event  
during membrane fusion. It is also worth noting that a very recent study by Bank-Wolf *et al.*  
has identified a position two residues downstream of the isoleucine to threonine substitution  
where an aspartate residue was found in all examined non-FIP associated FCoVs (5 from 5)  
but was replaced by a tyrosine in a significant proportion (5 from 9) of the FIP-associated  
315 FCoVs (Bank-Wolf *et al.*, 2014). Neither the isoleucine to threonine nor aspartate to tyrosine  
substitutions consistently discriminate between FIP and non-FIP FCoVs in the wider  
alignment of 29 type 1 FCoV S protein amino acid sequences that we have examined (data  
not shown) but, again, we think they may represent substitutions that are functionally related  
and could be relevant to the development of FIP.

320 The comparative sequence approach taken by ourselves and others has identified a  
number of potentially interesting mutations in the coding sequences of non-FIP and FIP  
associated FCoVs. In the future, this approach can be extended, i.e. a larger collection of

well-defined clinical samples should be analysed, and it can be refined. For example, to distinguish mutations that may relate to the tropism of FCoV from those that may relate to virulence, we suggest it would be important to obtain sequence data from a virus population that infects monocytes but is not able to replicate at a high level. Clearly obtaining appropriate clinical samples (e.g., blood monocytes from clinically healthy, FCoV infected cats) would not be easy but it would be very illuminating. The idea that a virus has to undergo sequential mutation *in vivo* in order to cause a specific disease is not unique to FIP (see, for example, the review on measles virus pathogenesis by de Vries *et al.* (de Vries *et al.*, 2012)) but, we suggest, it deserves closer attention in a number of veterinary and human diseases.

Nevertheless, this sequencing approach is ultimately limited. As has been stated before, compelling evidence that any specific mutation in the FCoV genome is important for the development of FIP will require the use of well-defined and characterized viruses produced by reverse genetics and a valid experimental model of FIP. With respect to reverse genetics, there are a number of robust reverse genetic systems available for coronaviruses, in general, and for particular strains of FCoV (namely the type 2 FCoV strain 79-1146 and the cell culture adapted type1 FCoV strain Black) (Thiel *et al.*, 2014). The pressing need, however, is for a robust reverse genetic system that can be applied to field strains of type 1 FCoV. In our opinion, the bottleneck is not the molecular manipulation of the FCoV genome but, rather, the ability to propagate type 1 FCoVs in cell culture without extensive adaptation. Although there has been recent progress in the development of enterocyte cell lines that propagate type 1 FCoVs (Desmarests *et al.*, 2013), we believe that a more robust cell culture system that allows for the propagation of high virus titres and the rescue of both mutated and non-mutated virus will be needed. To achieve this, identification of both the cellular receptor and attachment factors specific to type 1 FCoVs and the transduction of well-established, continuous, feline cell lines that can be easily maintained will be essential.

The second required element, a valid experimental model of FIP, is also more challenging than it may, at first, appear. For example, many of the commonly used animal



models of FIP often involve intraperitoneal inoculation. If the natural course of FCoV infection involves sequential replication in the gut, low level replication in blood monocytes and high level replication in monocytes and macrophages, and each transition is associated with the selection of specific mutants, then this has to be reproduced in any valid experimental model.

355 In a recent report, Tekes *et al.* showed that intraperitoneal infection of cats with a recombinant form of the FCoV 79-1146 strain robustly induced FIP (Tekes *et al.*, 2012). Strikingly, the virus re-isolated from these cats demonstrated that there had been strong selection for a virus that reverted to encode an intact 3c protein. This is, in our view, good evidence that FIP results from an infection that involves initial replication in the gut.

360 In summary, our results contribute to a better understanding of FCoV genomic mutations that may or may not be used as markers of the virus phenotype. It is also clear from the results that the relationship between the viral genotype and the development of FIP is complex. The further analysis of complete FCoV genomes in defined clinical samples, a robust reverse genetics system that can be applied to field strains of serotype 1 FCoV, and  
365 the development of valid experimental models of FIP will all be needed to throw further light on this relationship.

## Methods

### 370 *Clinical samples and RNA extraction*

The samples selected for this study were fecal samples from three healthy kittens and post-mortem tissue lesion samples from three kittens with FIP. These samples were all obtained from a previously reported epizootic outbreak at a single-site UK feline rescue center (Barker *et al.*, 2013). The three tissue lesion samples, designated here as 26M (mesentery), 27C (colonic lymph node) and 28O (omentum), were from cats F/FIP, Z/FIP and J/FIP in the previous study (Barker *et al.*, 2013) and had been collected within 2 h of death, placed in RNeasy lysis buffer (Life Technologies) for 24-48 h at 4°C and then, after discarding the RNeasy lysis buffer, stored at -80°C. The diagnosis of FIP was confirmed by post mortem examination including histopathology and immunohistochemistry for the demonstration of FCoV antigen in lesions (Kipar *et al.*, 1998). The fecal samples (65F, 67F and 80F, previously named #65, #67 and #80) were collected from the healthy cats within one month of euthanasia of the cats with FIP (Barker *et al.*, 2013). Samples 80F and 27C were from cats that were littermates and were housed within the same pen. All three cats that provided fecal samples remained alive and without any clinical signs that could be suggestive of FIP for over 1 year post sampling. Fecal samples were stored at -80°C immediately after collection.

Total RNA was extracted and purified from 20 mg of tissue with a RNeasy RNA kit (Macherey-Nagel) based on the method described by Dye and colleagues (Dye *et al.*, 2008; Dye & Siddell, 2007). Briefly, 20 mg of each tissue sample was disrupted in a 2 ml tube by adding 500 µl lysis buffer containing 1% β-mercaptoethanol (v/v) and a 5 mm stainless steel ball bearing. The sample was homogenized using a TissueLyser II (Qiagen) at 30 Hz for 2 minutes and 470 µl of lysate was added to a filter column and centrifuged for 30 seconds at 10,000 x g. A 350 µl aliquot of the filtrate was added to 250 µl of ethanol and run through a binding column to which DNase I was added to remove genomic DNA. Following multiple washes, the RNA was eluted into 50 µl nuclease-free water. The RNeasy RNA kit was

also used to extract RNA from fecal samples using a method based on that described by Dye *et al.* (Dye *et al.*, 2008). A fecal suspension was produced by vortexing 0.5 g feces and 4.5 ml phosphate buffered saline 5 times for 30 seconds. Subsequently, 100 µl of this suspension was centrifuged for 2 minutes at 10,000 x g, and the supernatant removed and  
400 added to 350 µl of lysis buffer containing 1% β-mercaptoethanol (v/v). The protocol described above (from the filter column) was then followed.

#### *Histology and Immunohistochemistry*

Formalin-fixed tissue samples (26M, 27C, 28O) were routinely paraffin wax  
405 embedded and examined histologically to confirm the presence of typical FIP lesions. The immunohistochemistry served to demonstrate FCoV antigen within lesions, as described previously (Kipar *et al.*, 1998).

#### *Quantitative RT-PCR and virus-specific oligonucleotide primer design*

FCoV RNA was amplified from fecal and tissue samples using quantitative reverse  
410 transcriptase-polymerase chain reaction (qRT-PCR) as described previously (Dye *et al.*, 2008; Porter *et al.*, 2014). Oligonucleotide primer pairs (Table 3) were designed to produce a total of 7 RT-PCR products (amplicons) spanning the entire coding region of the FCoV genome using the MacVector Primer 3 software package. Initially, the primers were designed  
415 based on the genome sequence of FCoV C1Je, a serotype 1 FCoV (Dye & Siddell, 2007). The primers were then compared to an alignment of 29 serotype 1 FCoV genome sequences (ClustalW, available upon request) and optimized to allow for sequence variation and compatibility of the primer pairs. All primers were synthesized by Eurofins MWG Operon.

#### *One-Step RT-PCR*

  
420

FCoV-specific primers were used to reverse transcribe and amplify the viral RNA contained in 2 µl of extracted total RNA using the SuperScript III One-Step RT-PCR System with Platinum *Taq* High Fidelity (Life Technologies) as described by the manufacturer.

Briefly, a 50 µl reaction was set up on ice containing 2 µl RNA, 1 µl of 10 µM forward and 1 µl  
425 of 10 µM reverse primer, 25 µl 2X reaction mix (as supplied by the manufacturer), 2 µl  
SuperScript III RT/Platinum High Fidelity enzyme mix and water to a final volume of 50 µl.  
The reaction was incubated at 50°C for 50 minutes to allow cDNA synthesis, and then raised  
to 94°C for 2 minutes, followed by 41 cycles of 94°C for 15 seconds, 50-66°C (depending on  
the primer set) for 30 seconds and 68°C for 1 min/kb of product size. The annealing  
430 temperature for individual reactions was determined by the melting temperature of the  
primers used. The reaction underwent a final extension phase at 68°C for 7 minutes and was  
held at 4°C. For each amplicon, 5 µl of the PCR product was separated on a 1% agarose-  
TBE gel to confirm the PCR product size and to estimate the amount of DNA by comparison  
with standards. The PCR products were then pooled in approximately equimolar amounts  
435 and purified using Agencourt AmPure XP beads (Agencourt AMPure XP PCR Purification,  
Beckman Coulter), following the manufacturer's protocol, and eluted in nuclease-free water.

#### *Next generation sequencing*

Purified, pooled amplicons were sequenced at the University of Bristol Genomics  
440 Facility using the Ion Torrent platform (PGM with the 316v2 chip). A targeted, virus-specific  
cDNA single-end read library was produced. Briefly, DNA was fragmented using the Ion  
Xpress Plus Fragment Library Kit, ligated to Ion-compatible barcoded adaptors and size-  
selected for a target read length of 150-200 bases. The library was then amplified and  
purified using the Ion Plus Fragment Library Kit and the Agencourt AMPure XP Kit. The  
445 barcoded libraries were quantified and pooled in equimolar amounts using Bioanalyzer  
quantitation. Templates were prepared from the barcoded, pooled libraries using the Ion  
OneTouch 2 System. Routinely, four genomes were sequenced on a single 316v2 chip.

#### *Bioinformatics*

450 Sequence data were analyzed using bioinformatics tools including both *de novo*  
assembly (Trinity, <http://trinityrnaseq.sourceforge.net/>) and genome alignment (Bowtie2,

<http://bowtie-bio.sourceforge.net/bowtie2/index.shtml>) methods. Briefly, for samples 80F and 27C, a *de novo* consensus sequence was produced from the FASTQ reads using the Trinity assembled components and the MacVector assembly project tool (Grabherr *et al.*, 2011). In order to identify and correct possible errors in this assembly, the same FASTQ sequence files were then aligned to the assembled consensus sequence using Bowtie2. The alignments were visualized using the Integrative Genomics Viewer (IGV) and the consensus sequence manually corrected on the basis of the sequence reads. Subsequently, the FASTQ sequence reads for four samples (65F, 67F, 26M and 28O) were aligned to the corrected 80F consensus sequence using Bowtie2. Again, IGV was used to confirm each consensus sequence with regard to the relevant sequence reads. All of the assembled genome sequences were examined and confirmed to have the expected FCoV genome architecture and predicted ORFs. This workflow is illustrated in Fig. 5. For selected viral genes, the encoded protein sequences were derived and phylogenetic reconstruction was done using a neighbor-joining algorithm based upon an alignment generated by ClustalW (MacVector).

### **Ethic statement**

Historical samples were collected with full informed consent from owners that samples could be used for research purposes. The project has been approved under ethical review by the University of Bristol Animal Welfare and Ethical Review Board (VIN/14/013).

### **Acknowledgements**

CSL was supported by the Elizabeth Blackwell Institute and the Wellcome Trust Institutional Strategic Support Fund to the University of Bristol, with partial support from a Wellcome Trust Research Training Fellowship. EP was supported by the PetPlan Charitable Trust. The work of ST, CRH and SGS was supported by grants from the PetPlan Charitable Trust, the Royal College of Veterinary Surgeon's Trust Fund and the Langford Trust.

## References

- 480 **Addie, D. D. (2000).** Clustering of feline coronaviruses in multicat households. *Vet J* **159**, 8-9.
- Addie, D. D. & Jarrett, O. (1992).** A study of naturally occurring feline coronavirus infections in kittens. *Vet Rec* **130**, 133-137.
- 485 **Addie, D. D., Schaap, I. A., Nicolson, L. & Jarrett, O. (2003).** Persistence and transmission of natural type I feline coronavirus infection. *The Journal of general virology* **84**, 2735-2744.
- Bank-Wolf, B. R., Stallkamp, I., Wiese, S., Moritz, A., Tekes, G. & Thiel, H. J. (2014).** Mutations of 3c and spike protein genes correlate with the occurrence of feline infectious peritonitis. *Veterinary microbiology* **173**, 177-188.
- 490 **Barker, E. N., Tasker, S., Gruffydd-Jones, T. J., Tuplin, C. K., Burton, K., Porter, E., Day, M. J., Harley, R., Fews, D., Helps, C. R. & Siddell, S. G. (2013).** Phylogenetic analysis of feline coronavirus strains in an epizootic outbreak of feline infectious peritonitis. *Journal of veterinary internal medicine / American College of Veterinary Internal Medicine* **27**, 445-450.
- 495 **Bos, E. C., Luytjes, W. & Spaan, W. J. (1997).** The function of the spike protein of mouse hepatitis virus strain A59 can be studied on virus-like particles: cleavage is not required for infectivity. *Journal of virology* **71**, 9427-9433.
- Chang, H. W., de Groot, R. J., Egberink, H. F. & Rottier, P. J. (2010).** Feline infectious peritonitis: insights into feline coronavirus pathobiogenesis and epidemiology based on genetic analysis of the viral 3c gene. *The Journal of general virology* **91**, 415-420.
- 500 **Chang, H. W., Egberink, H. F., Halpin, R., Spiro, D. J. & Rottier, P. J. (2012).** Spike protein fusion peptide and feline coronavirus virulence. *Emerging infectious diseases* **18**, 1089-1095.
- Coleman, C. M. & Frieman, M. B. (2014).** Coronaviruses: important emerging human pathogens. *Journal of virology* **88**, 5209-5212.
- 505 **de Groot-Mijnes, J. D., van Dun, J. M., van der Most, R. G. & de Groot, R. J. (2005).** Natural history of a recurrent feline coronavirus infection and the role of cellular immunity in survival and disease. *Journal of virology* **79**, 1036-1044.
- de Haan, C. A., Stadler, K., Godeke, G. J., Bosch, B. J. & Rottier, P. J. (2004).** Cleavage inhibition of the murine coronavirus spike protein by a furin-like enzyme affects cell-cell but not virus-cell fusion. *Journal of virology* **78**, 6048-6054.
- 510 **de Vries, R. D., Mesman, A. W., Geijtenbeek, T. B., Duprex, W. P. & de Swart, R. L. (2012).** The pathogenesis of measles. *Current opinion in virology* **2**, 248-255.
- Desmarests, L. M., Theuns, S., Olyslaegers, D. A., Dedeurwaerder, A., Vermeulen, B. L., Roukaerts, I. D. & Nauwynck, H. J. (2013).** Establishment of feline intestinal epithelial cell cultures for the propagation and study of feline enteric coronaviruses. *Veterinary research* **44**, 71.
- 515 **Dewerchin, H. L., Cornelissen, E. & Nauwynck, H. J. (2005).** Replication of feline coronaviruses in peripheral blood monocytes. *Archives of virology* **150**, 2483-2500.
- 520 **Dye, C., Helps, C. R. & Siddell, S. G. (2008).** Evaluation of real-time RT-PCR for the quantification of FCoV shedding in the faeces of domestic cats. *Journal of feline medicine and surgery* **10**, 167-174.
- Dye, C. & Siddell, S. G. (2007).** Genomic RNA sequence of feline coronavirus strain FCoV C1Je. *Journal of feline medicine and surgery* **9**, 202-213.
- 525 **Grabherr, M. G., Haas, B. J., Yassour, M., Levin, J. Z., Thompson, D. A., Amit, I., Adiconis, X., Fan, L., Raychowdhury, R., Zeng, Q., Chen, Z., Mauceli, E., Hacohen, N., Gnirke, A., Rhind, N., di Palma, F., Birren, B. W., Nusbaum, C., Lindblad-Toh, K., Friedman, N. & Regev, A. (2011).** Full-length transcriptome assembly from RNA-Seq data without a reference genome. *Nature biotechnology* **29**, 644-652.
- 530

**Haijema, B. J., Volders, H. & Rottier, P. J. (2004).** Live, attenuated coronavirus vaccines through the directed deletion of group-specific genes provide protection against feline infectious peritonitis. *Journal of virology* **78**, 3863-3871.

**Heald-Sargent, T. & Gallagher, T. (2012).** Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. *Viruses* **4**, 557-580.

**Herrewegh, A. A., Smeenk, I., Horzinek, M. C., Rottier, P. J. & de Groot, R. J. (1998).** Feline coronavirus type II strains 79-1683 and 79-1146 originate from a double recombination between feline coronavirus type I and canine coronavirus. *Journal of virology* **72**, 4508-4514.

**Hsieh, L. E. & Chueh, L. L. (2014).** Identification and genotyping of feline infectious peritonitis-associated single nucleotide polymorphisms in the feline interferon-gamma gene. *Veterinary research* **45**, 57.

**Kipar, A., Bellmann, S., Kremendahl, J., Kohler, K. & Reinacher, M. (1998).** Cellular composition, coronavirus antigen expression and production of specific antibodies in lesions in feline infectious peritonitis. *Veterinary immunology and immunopathology* **65**, 243-257.

**Kipar, A., May, H., Menger, S., Weber, M., Leukert, W. & Reinacher, M. (2005).** Morphologic features and development of granulomatous vasculitis in feline infectious peritonitis. *Veterinary pathology* **42**, 321-330.

**Kipar, A. & Meli, M. L. (2014).** Feline infectious peritonitis: still an enigma? *Veterinary pathology* **51**, 505-526.

**Kipar, A., Meli, M. L., Baptiste, K. E., Bowker, L. J. & Lutz, H. (2010).** Sites of feline coronavirus persistence in healthy cats. *The Journal of general virology* **91**, 1698-1707.

**Licitra, B. N., Millet, J. K., Regan, A. D., Hamilton, B. S., Rinaldi, V. D., Duhamel, G. E. & Whittaker, G. R. (2013).** Mutation in spike protein cleavage site and pathogenesis of feline coronavirus. *Emerging infectious diseases* **19**, 1066-1073.

**Masters, P. S. & Perlman, S. (2013).** Coronaviridae. In *Fields virology*. Edited by D. M. Knipe, P. M. Howley, J. I. Cohen, D. E. Griffin, R. A. Lamb, M. A. Martin, V. R. Racaniello & B. Roizman. Philadelphia, PA: Lippincott Williams & Wilkins.

**Meli, M., Kipar, A., Muller, C., Jenal, K., Gonczi, E., Borel, N., Gunn-Moore, D., Chalmers, S., Lin, F., Reinacher, M. & Lutz, H. (2004).** High viral loads despite absence of clinical and pathological findings in cats experimentally infected with feline coronavirus (FCoV) type I and in naturally FCoV-infected cats. *Journal of feline medicine and surgery* **6**, 69-81.

**Millet, J. K. & Whittaker, G. R. (2014).** Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. *Proceedings of the National Academy of Sciences of the United States of America*.

**Pedersen, N. C. (2009).** A review of feline infectious peritonitis virus infection: 1963-2008. *Journal of feline medicine and surgery* **11**, 225-258.

**Pedersen, N. C. (2014a).** An update on feline infectious peritonitis: diagnostics and therapeutics. *Vet J* **201**, 133-141.

**Pedersen, N. C. (2014b).** An update on feline infectious peritonitis: virology and immunopathogenesis. *Vet J* **201**, 123-132.

**Pedersen, N. C., Liu, H., Gandolfi, B. & Lyons, L. A. (2014).** The influence of age and genetics on natural resistance to experimentally induced feline infectious peritonitis. *Veterinary immunology and immunopathology*.

**Pedersen, N. C., Liu, H., Scarlett, J., Leutenegger, C. M., Golovko, L., Kennedy, H. & Kamal, F. M. (2012).** Feline infectious peritonitis: role of the feline coronavirus 3c gene in intestinal tropism and pathogenicity based upon isolates from resident and adopted shelter cats. *Virus research* **165**, 17-28.

**Perlman, S. & Netland, J. (2009).** Coronaviruses post-SARS: update on replication and pathogenesis. *Nature reviews Microbiology* **7**, 439-450.

**Porter, E., Tasker, S., Day, M. J., Harley, R., Kipar, A., Siddell, S. G. & Helps, C. R. (2014).** Amino acid changes in the spike protein of feline coronavirus correlate with

systemic spread of virus from the intestine and not with feline infectious peritonitis. *Veterinary research* **45**, 49.

**Regan, A. D., Cohen, R. D. & Whittaker, G. R. (2009).** Activation of p38 MAPK by feline infectious peritonitis virus regulates pro-inflammatory cytokine production in primary blood-derived feline mononuclear cells. *Virology* **384**, 135-143.

**Reguera, J., Santiago, C., Mudgal, G., Ordone, D., Enjuanes, L. & Casasnovas, J. M. (2012).** Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies. *PLoS pathogens* **8**, e1002859.

**Satoh, R., Furukawa, T., Kotake, M., Takano, T., Motokawa, K., Gemma, T., Watanabe, R., Arai, S. & Hohdatsu, T. (2011).** Screening and identification of T helper 1 and linear immunodominant antibody-binding epitopes in the spike 2 domain and the nucleocapsid protein of feline infectious peritonitis virus. *Vaccine* **29**, 1791-1800.

**Tekes, G., Spies, D., Bank-Wolf, B., Thiel, V. & Thiel, H. J. (2012).** A reverse genetics approach to study feline infectious peritonitis. *Journal of virology* **86**, 6994-6998.

**Thiel, V., Thiel, H. J. & Tekes, G. (2014).** Tackling feline infectious peritonitis via reverse genetics. *Bioengineered* **5**.

**Wicht, O., Burkard, C., de Haan, C. A., van Kuppeveld, F. J., Rottier, P. J. & Bosch, B. J. (2014).** Identification and characterization of a proteolytically primed form of the murine coronavirus spike proteins after fusion with the target cell. *Journal of virology* **88**, 4943-4952.

**Ziebuhr, J. (2005).** The coronavirus replicase. *Current topics in microbiology and immunology* **287**, 57-94.



Table 1. Amino acid substitutions that partially or fully discriminate between the genome sequences derived from non-FIP (fecal) and FIP (tissue lesion) samples. The positions of the substitutions are indicated as the position of the relevant mutation/substitution based upon an alignment of the six FCoV genomes analyzed in this study (Supplementary File 1). The amino acid positions in the non-structural replicase proteins (nsps) refer to pp1ab.

Nucleotide position	Protein	65F	67F	80F	26M	27C	28O	Amino acid position
1758	nsp2	I	I	I	V	V	I	549
1794	nsp2	G	G	G	G	G	R	561
6553	nsp3	D	D	D	G	G	D	2147
14727	nsp12	Y	Y	Y	F <sup>+</sup>	F <sup>+</sup>	Y	4872
17883	nsp14	T	T	T	I	I	T	5924
19277	nsp16	N	N <sup>†</sup>	N	H	H	N	6389
21370	S	S	S	S	A	S	S	403
21377	S	I	I	I	I	I	T	405
22291	S	F	F	F	F	F	L	710
22361	S	S	S	S	I	I	S	733
22528	S	R	R	R	G	G	R	789
22539	S	R	R	R	R	R	S	792
22757	S	S	S	S	F	F	S	865
23302	S	M	M	M	L	L	L	1047
23486	S	I	I	I	T	T	T <sup>‡</sup>	1108
23589	S	K	K	K	N	N	K	1142
24190	S	P	P	P	P	P	S	1343
24298	S	E	E	E	Q	Q	E	1379
25447	3C	T	T	T	T	T	M	165
25580-25589	3C	(-)	(-)	(-)	(+)	(+)	(-)	Deletion
27228	N	S	S	S	L	L	S	170
28759	7B	L	L	L	F	L	L <sup>§</sup>	198

620       \* The consensus nucleotide constituted 83% (26M) and 55% (27C) of the sequence reads at this position.

† The consensus nucleotide constituted 60% of the sequence reads at this position.

‡ The consensus nucleotide constituted 75% of the sequence reads at this position.

§ The consensus nucleotide constituted 85% of the sequence reads at this position

625       In all other cases, the consensus nucleotide constituted more than 96% of the sequence reads at a given position.

(-) 3c protein gene was complete

(+) 3c protein gene had a deletion. The deletions were: 26M and 27C, nt 25584-25593 (10 nucleotides, AGGAGTTTAC).

630

Table 2. Amino acid substitutions that do not discriminate between the genome sequences derived from non-FIP (fecal) and FIP (tissue lesion) samples. The positions of the substitutions are indicated as the position of the relevant mutation/substitution based upon an alignment of the six FCoV genomes analyzed in this study (Supplementary file 1). The amino acid positions in the nsp proteins refer to pp1ab.

Nucleotide position	Protein	65F	67F	80F	26M	27C	28O	Amino acid position
813	nsp2	V	I	I	I	I	V	234
1794/1795	nsp2	E	G	G	G	G	R	561
2955	nsp3	A	T <sup>*</sup>	T	T	T	A	948
3082	nsp3	R	K <sup>†</sup>	K	K	K	R	990
3797	nsp3	Q	Q	H	Q	Q	Q	1228
5218	nsp3	V	A	A	A	A	V	1702
5337	nsp3	L	M	M	M	M	L	1742
6804	nsp3	A	S	A	A	A	A	2231
8939	nsp5	K	K	N	N	N	K	2942
14564	nsp12	A	A	P	P	P	A	4818
15185	nsp13	I	I	L	I	I	I	5025
20509/20510	S	A	P <sup>‡</sup>	L	P	P	A	116
20584	S	D	N	N	N	N	D	141
20861	S	S	S <sup>§</sup>	N	S	S	S <sup>  </sup>	233
20864	S	R	Q	R	Q	Q	R	234
20866	S	I	L <sup>¶</sup>	I	I	I	L	235
21275	S	R	R <sup>#</sup>	Q	R	R	R	371
21467	S	I	T	T	T	T	I	435
22151	S	R	K <sup>**</sup>	K	R	R	R	663
22332	S	I	I <sup>††</sup>	M	I	I	I	723
27273	N	L	Q	Q	Q	Q	L	185
27873	7A	H	Y <sup>‡‡</sup>	H	Y	Y	H	6

\* The consensus nucleotide constituted 71% of the sequence reads at this position.

640 † The consensus nucleotide constituted 72% of the sequence reads at this position.

‡ The consensus nucleotide constituted 71% of the sequence reads at this position.

§ The consensus nucleotide constituted 68% of the sequence reads at this position.

|| The consensus nucleotide constituted 85% of the sequence reads at this position.

¶ The consensus nucleotide constituted 71% of the sequence reads at this position.

645 # The consensus nucleotide constituted 60% of the sequence reads at this position.

\*\* The consensus nucleotide constituted 59% of the sequence reads at this position.

†† The consensus nucleotide constituted 56% of the sequence reads at this position.

‡‡ The consensus nucleotide constituted 78% of the sequence reads at this position.

In all other cases, the consensus nucleotide constituted more than 96% of the sequence

650 reads at a given position.

Table 3. Sequences of oligonucleotide primers used in this study. All oligonucleotides are shown as 5' to 3' sequences. The positions of the oligonucleotides are given relative to the genome of FCoV C1Je [GenBank: DQ848678].

655

Name	Amplicon	Sequence	Position in C1Je	Length (nt)
F169	1	TAGGAACGGGGTTGAGAG	169-186	18
R6507	1	GTGCGAGAACRGCTTAA	6456-6467	18
F5562	2	GTTTGAAYTCACGTGGYCATT	5511-5531	21
R7490	2	GARGTCTTCATCWGAACCCAC	7441	21
F6943	3	GCTAGTGTTAGAAATGTCTGTGTT	6932	24
R12466	3	AAAAGCCCTACTAACGTGGTC	12421	21
F12224	4	CATCCTGCAATTGAYGGATTG	12173	21
R18105	4	TCCGGGTACATGTCTACGTTA	18054	21
F17830	5	GATTGGTCCATTGTGTACCC	17782	20
R20131b	5	AAARCCTTCCGATGACGAGGT	20080	21
F19786b	6	GTATTAAGRAGATGGTTGCCA	19735	21
R26007	6	ATAACCGCATGAGAAAAGGCT	25793	21
F24798	7	TAAAATGGCCKTGGTATGTGT	24601	21
R29508	7	TAGCTCTTCCATTGTTGGCTC	29167	21

## Figure legends

Figure 1. Genomic organization of feline coronavirus. Genomic ORFs are shown as boxes. Only pp1ab is shown as a translation product of the genomic RNA. The non-structural proteins nsp1–11 are translated from ORF1a (*dark grey*) and translation of the ORF1b proteins (nsp12–16) occurs following –1 ribosomal frameshifting (RFS). Nsp 11 is not depicted as it represents a short (nine amino acid) carboxyl extension of nsp10. Nsp9, single-stranded RNA-binding protein (ssRBP); nsp12, RNA-dependent RNA polymerase (RdRp); nsp13, helicase (Hel) and NTPase; nsp14, 3'→5' exoribonuclease (ExoN) and N7-methyltransferase (N7-MT); nsp15, uridylate-specific endonuclease (NendoU); nsp16, 2-O-methyltransferase (2-OMT).

Figure 2. Agarose gel electrophoresis of PCR amplicons 1-7 for tissue lesion samples 26M, 27C, 28O and fecal samples 65F, 67F, and 80F.

Figure 3. Coverage of sequence reads across the assembled FCoV genomes from fecal and tissue lesion samples. Sequence reads were aligned against the *de novo* assembled 80F target genome for the feces-derived samples 65F (A), 67F (B), 80F (C) and tissue lesion-derived samples, 26M (D), 27C (E), and 28O (F).

Figure 4. Phylogenetic analysis of the core RNA-dependent RNA polymerase domain of nsp12 (amino acids 4503 to 4807 in pp1ab, Supplementary file 1) for FCoV strains sequenced in this study and selected FCoV genome sequences. The phylogenetic tree was constructed by the neighbor-joining method from an alignment made with ClustalW (MacVector). GenBank accession numbers are shown for all sequences. Bootstrap values exceeded 60% at all nodes.

Figure 5. Sequence assembly workflow for FCoV genomes. Fecal samples 65F, 67F, 80F and tissue lesion samples 26M, 27C, 28O. ORFs, open reading frames.

Supplementary File 1. A nucleotide alignment of the six type 1 FCoV consensus genome sequences determined in this study. The alignment was produced using ClustalW (MacVector).



Figure 1  
[Click here to download Figure: Lewis et al Figure 1.pptx](#)




Figure 2

[Click here to download Figure: Lewis et al Figure 2.pptx](#)




Figure 3

[Click here to download Figure: Lewis et al Figure 3.pptx](#)



Figure 4  
[Click here to download Figure: Lewis et al Figure 4.pptx](#)





Figure 5  
[Click here to download Figure: Lewis et al Figure 5.pptx](#)



## Supplementary Material Files

[Click here to download Supplementary Material Files: Supplementary File 1. Genome alignments of sequenced feline coronaviruses.pdf](#)